You are about to leave the Clinical Value website now.


Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Quick Summary

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify Elecsys PIVKA-II and conventional Lumipulse PIVKA-II from the serum samples of patients with unresectable HCC undergoing systemic therapy.

You May Also Like

13 February 2024

The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital

Read More
7 November 2023

Value and Challenges for Precision Oncology Realisation in Real World Practice

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.